Hansoh Pharma entered into a strategic collaboration with Merck & Co. worth over $2 billion, granting Merck the exclusive global license for its investigational GLP-1 receptor agonist, HS-10535.
Johnson & Johnson announced its acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system (CNS) disorders.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction.
In recent years, a molecular target known as Claudin18.2 has emerged as a prominent target in the treatment of gastric cancer, pancreatic cancer, and various other solid tumors.